ABVX Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Abivax SA's net margin of --. Abivax SA's return on equity of -- beat DBV Technologies SA's return on equity of -280.59%.

Abivax SA has a consensus price target of $125.40, signalling upside risk potential of 9.51%. On the other hand DBV Technologies SA has an analysts' consensus of $20.57 which suggests that it could grow by 47.98%. Given that DBV Technologies SA has higher upside potential than Abivax SA, analysts believe DBV Technologies SA is more attractive than Abivax SA.

Abivax SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.

Abivax SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abivax SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Abivax SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Abivax SA's net income of -$54.9M is lower than DBV Technologies SA's net income of -$33M. Notably, Abivax SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abivax SA is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of -- compared to Abivax SA's net margin of --. Abivax SA's return on equity of -- beat Innate Pharma SA's return on equity of -72.79%.

Abivax SA has a consensus price target of $125.40, signalling upside risk potential of 9.51%. On the other hand Innate Pharma SA has an analysts' consensus of $5.15 which suggests that it could grow by 172.7%. Given that Innate Pharma SA has higher upside potential than Abivax SA, analysts believe Innate Pharma SA is more attractive than Abivax SA.

Abivax SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of -0.081, suggesting its less volatile than the S&P 500 by 108.148%.

Abivax SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abivax SA pays -- of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend.

Abivax SA quarterly revenues are --, which are larger than Innate Pharma SA quarterly revenues of --. Abivax SA's net income of -$54.9M is higher than Innate Pharma SA's net income of --. Notably, Abivax SA's price-to-earnings ratio is -- while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abivax SA is -- versus 24.41x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

Inventiva SA has a net margin of -- compared to Abivax SA's net margin of --. Abivax SA's return on equity of -- beat Inventiva SA's return on equity of --.

Abivax SA has a consensus price target of $125.40, signalling upside risk potential of 9.51%. On the other hand Inventiva SA has an analysts' consensus of $15.33 which suggests that it could grow by 271.27%. Given that Inventiva SA has higher upside potential than Abivax SA, analysts believe Inventiva SA is more attractive than Abivax SA.

Abivax SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Inventiva SA has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.433%.

Abivax SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abivax SA pays -- of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend.

Abivax SA quarterly revenues are --, which are larger than Inventiva SA quarterly revenues of --. Abivax SA's net income of -$54.9M is higher than Inventiva SA's net income of --. Notably, Abivax SA's price-to-earnings ratio is -- while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abivax SA is -- versus 24.04x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.

Sanofi has a net margin of -- compared to Abivax SA's net margin of 36.7%. Abivax SA's return on equity of -- beat Sanofi's return on equity of 12.45%.

Abivax SA has a consensus price target of $125.40, signalling upside risk potential of 9.51%. On the other hand Sanofi has an analysts' consensus of $60.13 which suggests that it could grow by 21.4%. Given that Sanofi has higher upside potential than Abivax SA, analysts believe Sanofi is more attractive than Abivax SA.

Abivax SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sanofi has a beta of 0.446, suggesting its less volatile than the S&P 500 by 55.394%.

Abivax SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanofi offers a yield of 4.43% to investors and pays a quarterly dividend of $2.20 per share. Abivax SA pays -- of its earnings as a dividend. Sanofi pays out 66.53% of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abivax SA quarterly revenues are --, which are smaller than Sanofi quarterly revenues of $12.2B. Abivax SA's net income of -$54.9M is lower than Sanofi's net income of $4.5B. Notably, Abivax SA's price-to-earnings ratio is -- while Sanofi's PE ratio is 12.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abivax SA is -- versus 2.85x for Sanofi. Usually stocks with elevated PS ratios are considered overvalued.